Increased incidence of antiretroviral drug discontinuation among patients with viremic hepatitis C virus coinfection and high hyaluronic acid, a marker of liver fibrosis.
Cast your vote
You can rate an item by clicking the amount of stars they wish to award to this item.
When enough users have cast their vote on this item, the average rating will also be shown.
Your vote was cast
Thank you for your feedback
Thank you for your feedback
Rockstroh, Juergen K
de Wit, Stephane
Mitsura, Victor M
Lundgren, Jens D
MetadataShow full item record
CitationAIDS 2014, 28 (4):577-87
AbstractMost antiretroviral drugs are metabolized by the liver; hepatic disease or liver damage as a result of hepatitis C virus (HCV) could impair this metabolism leading to an increased risk of drug toxicity. This study aimed to determine the risk of antiretroviral drug discontinuation among HCV/HIV coinfected patients.
EuroSIDA patients taking combination antiretroviral therapy were included. Poisson regression identified factors associated with antiretroviral treatment discontinuation.
A total of 9535 HIV-positive patients with known HCV status were included (6939 HCVAb-negative; 2596 HCVAb-positive at baseline). Viremic HCV infection was associated with a 44% increased risk of antiretroviral drug discontinuation compared with aviremic infection [adjusted incidence rate ratio, aIRR: 1.44 (95% confidence interval, CI 1.22-1.69)]; this relationship was largest among nonnucleoside reverse transcriptase inhibitors [aIRR: 1.59 (95% CI 1.18-2.14)]. In the subset of 935 HIV-positive patients also HCV-positive or HBV-positive with plasma hyaluronic acid measured, hyaluronic acid more than 100 ng/ml was associated with a 37% increased risk of antiretroviral drug discontinuation [aIRR: 1.37 (95% CI 1.08-1.73) vs. hyaluronic acid ≤100 ng/ml] and the effect of HCV viremia became nonsignificant; the largest drug association was seen for protease inhibitors [aIRR: 1.40 (95% CI 1.04-1.89)].
HCV viremia and high levels of hyaluronic acid predict antiretroviral drug discontinuation. Evidence was also found to suggest a link between impaired liver function and protease inhibitor toxicity.
DescriptionTo access publisher's full text version of this article click on the hyperlink at the bottom of the page
RightsArchived with thanks to AIDS (London, England)
- Does hepatitis C viremia or genotype predict the risk of mortality in individuals co-infected with HIV?
- Authors: Rockstroh JK, Peters L, Grint D, Soriano V, Reiss P, Monforte Ad, Beniowski M, Losso MH, Kirk O, Kupfer B, Mocroft A, EuroSIDA in EuroCoord.
- Issue date: 2013 Aug
- Positive impact of hepatitis C virus (HCV) treatment on antiretroviral treatment adherence in human immunodeficiency virus-HCV coinfected patients: one more argument for expanded access to HCV treatment for injecting drug users.
- Authors: Roux P, Fugon L, Winnock M, Salmon-Céron D, Lacombe K, Sogni P, Spire B, Dabis F, Carrieri MP, ANRS-CO-13-HEPAVIH Study Group.
- Issue date: 2012 Jan
- Impact of HAART exposure and associated lipodystrophy on advanced liver fibrosis in HIV/HCV-coinfected patients.
- Authors: Loko MA, Bani-Sadr F, Winnock M, Lacombe K, Carrieri P, Neau D, Morlat P, Serfaty L, Dabis F, Salmon D, ANRS CO 13 HEPAVIH Study Group.
- Issue date: 2011 Jul
- Hepatic steatosis in HIV-HCV coinfected patients receiving antiretroviral therapy is associated with HCV-related factors but not antiretrovirals.
- Authors: Martinez V, Ta TD, Mokhtari Z, Guiguet M, Miailhes P, Valantin MA, Charlotte F, Bertheau P, Molina JM, Katlama C, Caumes E
- Issue date: 2012 Jul 9
- Are specific antiretrovirals associated with an increased risk of discontinuation due to toxicities or patient/physician choice in patients with hepatitis C virus coinfection?
- Authors: Mocroft A, Rockstroh J, Soriano V, Ledergerber B, Kirk O, Vinogradova E, Reiss P, Katlama C, Phillips AN, Lundgren JD, EuroSIDA Study Group.
- Issue date: 2005